-
821
Table 5_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.docx
منشور في 2025"…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …"
-
822
Image 4_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.tiff
منشور في 2025"…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …"
-
823
Image 9_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.tiff
منشور في 2025"…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …"
-
824
Image 5_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.tiff
منشور في 2025"…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …"
-
825
Table 2_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.docx
منشور في 2025"…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …"
-
826
Data Sheet 1_The flavonoid of Dracocephalum heterophyllum Benth. ameliorates cerebral small vessel disease by inhibiting the autophagy via Angs-Tie2 signaling pathway.docx
منشور في 2025"…Background<p>Cerebral small vessel disease (CSVD) is a common cause of stroke and vascular cognitive impairment. …"
-
827
Effect of Molecular Structure on the B3LYP-Computed HOMO–LUMO Gap: A Structure −Property Relationship Using Atomic Signatures
منشور في 2025"…The atomic fragments containing π-bonds in various aromatic compounds were found to be the most significant atomic Signatures, explaining nearly 50% of the variance in the data, with regression coefficients that decreased <i>E</i><sub>gap</sub>. …"
-
828
-
829
Table 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.docx
منشور في 2025"…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…"
-
830
Data Sheet 2_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.pdf...
منشور في 2025"…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…"
-
831
Data Sheet 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.zip...
منشور في 2025"…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…"
-
832
-
833
-
834
-
835
-
836
-
837
-
838
-
839
No signs of toxicity of HIFN treatment were reported in the histopathological analysis.
منشور في 2025الموضوعات: -
840
Serum chemistry in the animals after chronic treatment with HIFN or vehicle.
منشور في 2025الموضوعات: